This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by young adults requires effective and accessible treatments to support current users to quit. Research shows this group prefers and benefits from newer methods of treatment delivery such as digital interventions. ACT on Vaping is a digital therapeutic intended to deliver behavioral therapy to young adults who vape to motivate and support abstinence from all nicotine and tobacco products. The app contains sessions that promote awareness of cues that trigger tobacco use and teach skills for responding to these triggers in a way that is tailored for the participant's readiness to quit. Receiving access to the ACT on Vaping app may be effective in helping young adults quit vaping.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants use the ACT on Vaping app (Version A) and receive a text messaging program to motivate and support quitting. Participants also receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.

ARM II: Participants use the ACT on Vaping app (Version B) and receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.

After completion of study intervention, participants are followed up at 3, 5.5, and 6 months.

Inclusion Criteria:

• Age 18-30
• Current weekly user of e-cigarette product(s) for the last 30 days
• Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent)
• Experience downloading and using one or more apps on their smartphone
• Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app
• Has access to text messaging
• Has an email address
• United States (US) resident, with a US mailing address
• Willing to complete all study procedures
• Comfortable reading and writing in English

Exclusion Criteria:

• Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial participation)
• Member of the same household as another research participant
• Currently in prison
• Google voice number as sole phone number, due to its association with fraudulent study entry attempts
• Is ineligible per fraud prevention protocol
• Employees/family of investigator or study center

We plan to preserve & share the following scientific data:

• Survey Data: De-identified individual & aggregate survey data (including raw and recoded data) necessary to replicate main outcomes will be shared
• App utilization data: Individual level, de-identified aggregate data necessary to replicate main outcomes will be shared

Documentation made publicly available to the research community will also include PDFs of the following:

• Survey instruments with proprietary measures redacted
• A description of the data collection methods
• Copies of study consent forms & other relevant documentation of IRB approval & limitations on data sharing or usage
• Survey codebook
• Methods used to code or summarize open-text survey responses
• Steps taken to remove direct & indirect identifiers in the data
• Description of the software & analytical methods used in survey data analyses
• Code used in data analyses

Final data submission and release of data used in publications will occur at the time of publication. Other shared data will be made available at or before the end of the project period. We will follow the data retention plan of the final selected repository, but at a minimum, we intend to ensure that data is available for a period of not less than 5 years after the end of this trial.

All data sharing will be done in compliance with NIH data sharing policies, applicable laws and regulations, and in accordance with guidance from journal publishers. At this time, we plan to share scientific data and meta-data in NCI's Cancer Data Service (CDS). CDS allows open and controlled access to data to ensure access is provided to qualified researchers, data access is tracked, and users understand how to cite and credit use of the data. Data will only be shared for non-profit, non-commercial and non-proprietary purposes to qualified researchers or as allowed by CDS. Based on the nature of the data, which is not sensitive, we anticipate making it publicly available (as opposed to controlled access) but will follow final recommendations from the IRB as to whether access should be controlled.

The control app will also be called ACT on Vaping in participant-facing materials, for blinding purposes; Any outcome evaluator who has direct contact with participants will remain blinded to treatment group assignment.